Search

Daotai L Nie

age ~56

from Springfield, IL

Also known as:
  • Daotai Nie
  • I Nie
  • Nie Daotai

Daotai Nie Phones & Addresses

  • Springfield, IL
  • 152 Hillcrest St, Grosse Pointe, MI 48236 • 3136479616
  • 491 Hancock St, Detroit, MI 48201 • 3138328319
  • Grosse Pointe Farms, MI
  • Columbia, SC
  • 7400 Wentworth Dr, Springfield, IL 62711 • 3136479616

Work

  • Position:
    Production Occupations

Us Patents

  • Fc101 As A Method Of Treatment For Cancer

    view source
  • US Patent:
    6660765, Dec 9, 2003
  • Filed:
    Aug 2, 2002
  • Appl. No.:
    10/211466
  • Inventors:
    Roy E. Wuthier - Columbia SC
    Daotai Nie - Grosse Pointe Farms MI
  • Assignee:
    University of South Carolina - Columbia SC
  • International Classification:
    A61K 31335
  • US Classification:
    514450
  • Abstract:
    The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
  • Fc101 And Analogs As A Method Of Treatment For Cancer

    view source
  • US Patent:
    7078433, Jul 18, 2006
  • Filed:
    Oct 29, 2003
  • Appl. No.:
    10/696760
  • Inventors:
    Roy E. Wuthier - Columbia SC,
    Daotai Nie - Grosse Pointe Farms MI,
  • Assignee:
    University of South Carolina - Columbia SC
  • International Classification:
    A01N 43/16
    A61K 31/35
  • US Classification:
    514460
  • Abstract:
    The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
  • Use Of An Angiogenesis Inhibitor As A Lead Compound In Drug Development

    view source
  • US Patent:
    20010011100, Aug 2, 2001
  • Filed:
    Mar 29, 2001
  • Appl. No.:
    09/821196
  • Inventors:
    Roy Wuthier - Columbia SC,
    Daotai Nie - Detroit MI,
  • International Classification:
    A61K031/366
  • US Classification:
    514/456000
  • Abstract:
    The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
  • Angiogenesis Inhibitor For The Treatment Of Endothelial Cell Proliferation

    view source
  • US Patent:
    62253409, May 1, 2001
  • Filed:
    Mar 30, 1999
  • Appl. No.:
    9/281577
  • Inventors:
    Roy E. Wuthier - Columbia SC
    Daotai Nie - Detroit MI
  • Assignee:
    University of South Carolina - Columbia SC
  • International Classification:
    A61K 3135
  • US Classification:
    514456
  • Abstract:
    The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
  • Angiogenesis Inhibitor For The Treatment Of Cancer

    view source
  • US Patent:
    59326115, Aug 3, 1999
  • Filed:
    Nov 21, 1997
  • Appl. No.:
    8/975813
  • Inventors:
    Roy E. Wuthier - Columbia SC
    Daotai Nie - Detroit MI
  • Assignee:
    University of South Carolina - Columbia SC
  • International Classification:
    A61K 3135
  • US Classification:
    514456
  • Abstract:
    The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.

Facebook

Daotai Nie Photo 1

Daotai Nie

view source

Get Report for Daotai L Nie from Springfield, IL, age ~56
Control profile